Retatrutide, a innovative dual-acting glucose-dependent incretin mimetic, represents a significant leap in peptide treatments for the management of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor agonist and a GIP receptor agonist, offering a mor